Etinilestradiol/Drospirenona Diario Cinfalab

Etinilestradiol/Drospirenona Diario Cinfalab is a combined oral contraceptive containing ethinylestradiol and drospirenone. It is used for birth control and may help manage hormonal acne. This medication is manufactured by Laboratorios Cinfa S.A. in the EU.

Etinilestradiol/Drospirenona Diario Cinfalab is primarily used as a contraceptive to prevent pregnancy. It works by inhibiting ovulation and altering the cervical mucus to prevent sperm from reaching the egg. Additionally, it may be prescribed to manage symptoms of hormonal acne due to its anti-androgenic properties. This medication is taken orally and contains lactose.

Common effects of Etinilestradiol/Drospirenona Diario Cinfalab may include changes in menstrual bleeding patterns, such as lighter or more regular periods. Some users may experience breast tenderness, headaches, or nausea. These effects vary and typically subside as the body adjusts to the medication.

This medication should be used with caution in individuals with a history of blood clots, high blood pressure, or liver disease. It is important to inform your healthcare provider about any pre-existing conditions or allergies before starting this treatment. Regular monitoring may be required to ensure safety and effectiveness.

Etinilestradiol/Drospirenona Diario Cinfalab may interact with certain medications, including those that induce liver enzymes, such as some anticonvulsants and antibiotics. Alcohol consumption should be moderated, as it can affect the metabolism of the drug. Always consult a healthcare provider before combining this medication with other treatments.